Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K. Chang, Marjorie Z. Imperial, Patrick P. J. Phillips, Gustavo E. Velásquez et autres
The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was 12-month tuberculosis disease free survival, while the primary safety outcome was the …
us, Ouganda, gb, Afrique du Sud, vn, ht, Zimbabwe, in, br, Malawi, Kenya, pe, th (code pays fourni par la source)